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Abstract The role of ATP and its stable analogue ATPγS
[adenosine-5′-o-(3-thio)triphosphate] was studied in rat
hippocampal neurotransmission under normoxic conditions
and during oxygen and glucose deprivation (OGD). Field
excitatory postsynaptic potentials (fEPSPs) from the den-
dritic layer or population spikes (PSs) from the soma were
extracellularly recorded in the CA1 area of the rat hippo-
campus. Exogenous application of ATP or ATPγS reduced
fEPSP and PS amplitudes. In both cases the inhibitory
effect was blocked by the selective A1 adenosine receptor
antagonist DPCPX (8-cyclopentyl-1,3-dipropylxanthine)
and was potentiated by different ecto-ATPase inhibitors:
ARL 67156 (6-N,N-diethyl-D-β,γ-dibromomethylene),
BGO 136 (1-hydroxynaphthalene-3,6-disulfonate) and PV4
[hexapotassium dihydrogen monotitanoun-decatungstocobal-
tate(II) tridecahydrate, K6H2[TiW11CoO40]·13H2O]. ATPγS-
mediated inhibition was reduced by the P2 antagonist
suramin [8-(3-benzamido-4-methylbenzamido)naphthalene-
1,3,5-trisulfonate] at the somatic level and by other P2
blockers, PPADS (pyridoxalphosphate-6-azophenyl-2′,
4′-disulfonate) and MRS 2179 (2′-deoxy-N
6-methyladeno-
sine 3′,5′-bisphosphate), at the dendritic level. After removal
of both P2 agonists, a persistent increase in evoked synaptic
responses was recorded both at the dendritic and somatic
levels. This effect was prevented in the presence of different
P2 antagonists. A 7-min OGD induced tissue anoxic
depolarization and was invariably followed by irreversible
loss of fEPSP. PPADS, suramin, MRS2179 or BBG (brilliant
blue G) significantly prevented the irreversible failure of
neurotransmission induced by 7-min OGD. Furthermore, in
the presence of these P2 antagonists, the development of
anoxic depolarization was blocked or significantly delayed.
Our results indicate that P2 receptors modulate CA1 synaptic
transmission under normoxic conditions by eliciting both
inhibitory and excitatory effects. In the same brain region, P2
receptor stimulation plays a deleterious role during a severe
OGD insult.
Key words ecto-ATPaseinhibitors.extracellular
recordings.hippocampalslices.OGD.P2purinergic
receptors.synapticpotentials
Abbreviations
aCSF artificial cerebrospinal fluid
AD anoxic depolarization
ARL 67156 6-N,N-diethyl-D-β,γ-dibromomethylene
ATP
ATPγS adenosine-5′-o-(3-thio)triphosphate
BBG brilliant blue G
BGO 136 1-hydroxynaphthalene-3,6-disulfonate
CNS central nervous system
DC direct current
DMSO dimethylsulphoxide
DPCPX 8-cyclopentyl-1,3-dipropylxanthine
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Introduction
The role of adenosine triphosphate (ATP) as a neurotrans-
mitter has been largely demonstrated both in the peripheral
and the central nervous system (CNS) (for a review, see:
[1]). In the hippocampus, ATP is released from neurones
[2–4] and astrocytes [5, 6] through various mechanisms,
including a vesicular mode [7]. ATP triggers pathophysio-
logical responses by stimulating purinergic P2 receptors,
classified as P2X and P2Y [1, 8–10]. P2X receptors are
ligand-gated ion channels permeable to cations (Na
+,K
+
and Ca
2+) that are present as homo- and heteromeric trimers
on the cell surface [11, 12]. Seven different subunits of P2X
purinergic receptors (P2X1-7) have been cloned to date in
mammals. P2Y receptors are G protein-coupled receptors
showing the typical structure of a single subunit with seven
membrane-spanning domains [13]. Eight subtypes of
metabotropic P2Y receptors (P2Y1,2,4,6,11,12,13,14, plus the
recently deorphanized GPR17 receptor by Abbracchio and
colleagues: see [14]) have been cloned to date [15]. Both
P2X and P2Y receptors are widely expressed in many brain
areas, including the hippocampus [16, 17].
Both potentiating and suppressing effects of exogenous-
ly applied ATP on synaptic transmission have been reported
[18–20], depending on varying expression and localization
of purinergic receptor subtypes.
It has been demonstrated that ATP acts as a fast
neurotransmitter in the CNS. In fact, P2X-mediated synaptic
currents are present in different brain areas: the CA3 [3] and
CA1 [21] hippocampal regions, the somatosensory cortex
[22], the medial habenula [23], locus coeruleus [24] and
neurones of the trigeminal mesencephalic nucleus [25].
At the presynaptic level, P2X receptor activation
enhances glutamate [4, 19, 26] and γ-aminobutyric acid
(GABA) [27–29] release from neurones in the hippocam-
pus. An excitatory effect of 2-methylthio-ATP (2meS-ATP)
and of ATP itself, but only in the presence of 8-cyclopentyl-
1,3-dipropylxanthine (DPCPX), is exerted in neurones of
the rat prefrontal cortex [30].
Studies in primary cultures of rat hippocampal cells
demonstrated that tonic- and activity-dependent release of
ATP by astrocytes can stimulate presynaptic P2Y receptors
with a consequent inhibition of glutamate release [5, 6, 31].
Similarly, it has been demonstrated that synaptic transmis-
sion is markedly inhibited by exogenous application of ATP
and stable analogues in a concentration-dependent way
both in hippocampal [32–35] and prefrontal cortex slices
[36]. These effects are theophylline sensitive but quite
unaffected by suramin, pyridoxalphosphate-6-azophenyl-
2′,4′-disulfonate (PPADS) and ecto-ATPase/ecto-nucleotid-
ase inhibitors.
It is generally known that extracellular ATP is rapidly
converted into adenosine through ecto-nucleotidases [37],
with subsequent activation of P1 adenosine receptors. The
adenosine A1 subtype [33, 38] is particularly expressed in
the hippocampus. Under physiological conditions, the tonic
role of extracellular adenosine in inhibiting CA1 hippo-
campal neurotransmission through A1 receptor activation
has been well described [39, 40]. First, the inhibition
exerted by ATP on hippocampal neurotransmission was
attributed to its rapid conversion (<1 s) to adenosine by
ecto-ATPases and ecto-nucleotidases and subsequent acti-
vation of A1 receptors based on the observation that this
response was theophylline sensitive [32, 33, 41] and absent
in A1 knockout mice [34]. On the other hand, a more
detailed observation of adenine nucleotide-evoked effects
and the synthesis of new pharmacological tools revealed a
P2-mediated inhibition of synaptic transmission in the
hippocampus [17, 35, 36].
In general, it appears that P2Y receptor stimulation is
mostly associated with an inhibition of synaptic transmis-
sion [17, 35, 36], while P2X activation is mainly correlated
with an increase in excitatory neurotransmission [3, 4, 21–
24, 42, 43].
The relative contribution of P1 and P2 receptor activa-
tion to the total hippocampal neurotransmission is still to be
clarified (see [17, 34]).
The role of P2 receptors may become relevant during
pathological conditions such as ischaemia. Evidence of an
increased outflow of radioactive ATP from hippocampal
slices during ischaemic-like conditions was reported by
Juranyi et al. [44] and the first demonstration that ATP
outflow increases in vivo during the induction of focal
ischaemia in the rat was reported by Melani et al. [45].
Evidence supports the idea that, under such pathological
conditions, released ATP may exert a cytotoxic role.
Intrastriatal ATP injection in rats induced, 24 h later, a
clearly lesioned area [46]. The ATP-induced damage was
concentration-dependent, mimicked by ATPγS and α,β
meATP (but not by ADP or adenosine) and blocked by
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Suramin, another non-specific P2 receptor antagonist,
administered 30 min before occlusion of the middle
cerebral artery, resulted in a significant decrease in infarct
and oedema volume 6 h after brain injury [47]. In
agreement, it has been demonstrated that RB2 [48] and
PPADS [49] improve the neurological deficit and reduce
the damage induced in rats in a model of focal ischaemia in
vivo. Protective effects of P2 receptor antagonists [suramin,
brilliant blue G (BBG) and RB2] on cell survival were also
demonstrated in organotypic hippocampal slices exposed to
oxygen and glucose deprivation (OGD) [50, 51].
In this work we investigated the role of P2 purinergic
receptor activation in CA1 neurotransmission in rat hippo-
campal slices under normoxic and ischaemia-like condi-
tions, through the application of different P2 purinergic
receptor agonists and antagonists.
Methods
All animal procedures were conducted according to the
European Community Guidelines for Animal Care, DL
116/92, application of the European Communities Council
Directive (86/609/EEC). Experiments were carried out on
acute rat hippocampal slices, prepared as previously
described [52, 53].
Preparation of slices
Male Wistar rats (Harlan Italy, Udine, Italy, 150–200 g
body weight) were anaesthetized with ether and decapitated
with a guillotine. The hippocampi were rapidly removed
and placed in ice-cold oxygenated (95% O2–5% CO2)
artificial cerebrospinal fluid (aCSF) of the following
composition (mM): NaCl 124, KCl 3.33, KH2PO4 1.25,
MgSO4 1.4, CaCl2 2.5, NaHCO3 25 and D-glucose 10.
Slices (400 μm nominal thickness) were cut using a
McIlwain tissue chopper (Mickle Laboratory Engineering,
Co. Ltd., Gomshall, UK) and kept in oxygenated aCSF for
at least 1 h at room temperature. A single slice was then
placed on a nylon mesh, completely submerged in a small
chamber (0.8 ml) and superfused with oxygenated aCSF
(30–32°C) at a constant flow rate of 1.5 ml min
−1. The
treated solutions reached the preparation in 60 s and this
delay was taken into account in our calculations.
Extracellular recordings
Test pulses (80 μs, 0.066 Hz) were delivered through a
bipolar nichrome electrode positioned in the stratum
radiatum of the CA1 region of the hippocampus to
stimulate the Schaffer collateral-commissural pathway.
Evoked potentials were extracellularly recorded with glass
microelectrodes (2–10 MΩ, Clark Electromedical Instru-
ments, Panghourne, UK) filled with 150 mM NaCl. The
recording electrode was placed at the soma or at the dendritic
level of the CA1 region to record population spikes (PSs) or
field excitatory postsynaptic potentials (fEPSPs), respective-
ly. Responses were amplified (BM 622, Mangoni, Pisa,
Italy), digitized(samplerate:33.33 kHz),low-passfilteredin
direct current (DC) mode at 10 kHz and stored for later
analysis using LTP software facilities (version 2.30D,
William W. Anderson, 1991–2001).
The amplitude of fEPSP was measured as the difference
between the negative peak following the afferent fibre
volley and the baseline value preceding the stimulus
artefact. In some experiments both the amplitude and the
initial slope of fEPSP were quantified, but since no
appreciable difference between these two parameters was
observed under control conditions, in the presence of drugs
or during in vitro ischaemia, only the measure of the
amplitude was expressed in figures. The amplitude of PS
was measured as the difference between the peak negativity
and the averaged values of the two peak positivities
following the stimulus artefact.
When a stable baseline of evoked responses was
reached, fEPSP or PS amplitudes were routinely measured
and expressed as the percentage of the mean value recorded
5 min before the application of any treatment.
Stimulus-responsecurveswereobtainedbygradualincrease
instimulusstrengthat thebeginningandatrepresentativetimes
during each experiment, as indicated in the “Results” section.
The test stimulus strength was then adjusted to produce a
response whose amplitude was 40–50% of the maximum and
was kept constant throughout the experiment.
In a group of slices, simultaneously with fEPSP
amplitude, we also recorded anoxic depolarization (AD)
as negative shifts in the DC mode induced by 7-min OGD.
OGD conditions
Slices were perfused for 7 min with aCSF without glucose
and gassed with nitrogen (95% N2–5% CO2: OGD) as
indicated elsewhere [52, 53]. The effects of 7-min OGD in
hippocampal slices were evaluated by recording fEPSP
amplitude according to a previously described method [52,
53]. In a typical experimental day, a control slice was
submitted to 7 min of OGD. If the recovery of fEPSP
amplitude after 15 min of reperfusion with glucose-
containing and normally oxygenated aCSF was ≤15% of
the preischaemic value, a second slice from the same rat
was submitted to a 7-min OGD insult in the presence of the
P2 antagonist under investigation. To confirm the result
obtained in the treated group, a third slice was taken from
the same rat and another 7-min OGD was performed under
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slices was caused by the time gap between the experiments.
Drug application
Under normoxic conditions, ATP and its metabolically
stable analogue ATPγS were applied by superfusion for 10
min, a time that allowed us to record a stable response to
the compounds. The P2 purinergic antagonists (suramin,
PPADS, MRS 2179 and BBG) were applied 10 or 15 min
before, during and 5 min after the application of P2
agonists or the induction of OGD.
Ecto-ATPases (NTPDase1, 2 and 3) are responsible for
the degradation of extracellular ATP [54]. In the present
work, three different ecto-ATPase inhibitors were tested:
ARL 67156, BGO 136 and PV4. ARL 67156, a commonly
used ecto-ATPase inhibitor [55], was superfused at a
concentration of 50 μM, 20 min before and during ATP
or ATPγS application, in accordance with previous data in
the literature [43, 56]. However, it has been recently shown
that, at micromolar concentrations, ARL 67156 only
inhibits rat NTPDase1 and 3 transiently transfected in
Chinese hamster ovary cells, showing negligible activity on
NTPDase2 [57]. In addition, a possible interaction of this
ATP analogue with some P2Y receptors has been suggested
[58]. BGO 136 is a new ecto-ATPase inhibitor recently
available commercially. From the few data existing in the
literature at present, this compound is described as a
selective NTPDase1 and 2 blocker with Ki values in the
high micromolar range [59], being ineffective at concen-
trations below 5 mM ([60] and our unpublished observa-
tion). PV4 is a recently synthesized compound (not
available commercially) that belongs to a new class of
ecto-ATPase inhibitors: the polyoxotungstates [61]. PV4
strongly inhibits rat NTPDase1, 2 and 3 with Ki values in
the nanomolar range [61]. Its high affinity for these
enzymes renders it a useful tool (the best one available at
present) to inhibit extracellular ATP catabolism without
interfering with P2Y receptors, at least at 10 μM concen-
trations [61]. Since no data are available at present about
the application of BGO 136 or PV4 to brain slices, for
similarity with ARL 67156 we superfused these compounds
20 min before ATP application. In some cases hippocampal
slices were preincubated in the presence of the ecto-ATPase
inhibitors 1 h before starting the experiment, but since no
significant difference was found with non-incubated slices,
the results were pooled together.
Suramin is a non-specific and non-competitive antago-
nist of P2 purinergic receptors (either P2X or P2Y). It also
inhibits ecto-nucleotidase activity [57] and affects gluta-
matergic and GABAergic receptor activation in rat hippo-
campal slices [62]. PPADS is an antagonist at both P2Y
(P2Y1,2,4,6) and P2X1-5 receptors and is the compound most
used to block P2 purinergic receptor activation [1, 49].
BBG is a selective P2X7 receptor antagonist [63, 64]. MRS
2179 is a selective P2Y1 purinergic antagonist, at least at
concentrations below 1 μM[ 65, 66].
The concentrations used for each antagonist were chosen on
the basis of Ki values evaluated at rat P2 receptors [1, 67, 68].
All the P2 purinergic agonists and antagonists were
dissolved in distilled water and stock solutions at 100-
10,000 times the desired final concentration were stored at
−20°C. The drugs were dissolved in aCSF at the required
concentration immediately before superfusion.
DPCPX was dissolved in dimethylsulphoxide (DMSO)
and stock solutions were made to obtain concentrations of
DMSO lower than 0.001% in the superfusing aCSF.
Control experiments, carried out in parallel, showed that
this concentration of DMSO did not affect CA1 hippocam-
pal neurotransmission.
Paired-pulse facilitation
To elicit paired-pulse facilitation (PPF) of fEPSP, we
stimulated the Schaffer collateral-commissural fibres twice
with a 40-ms interpulse interval. The synaptic facilitation
was quantified as the ratio (P2/P1) between the amplitude
of the fEPSP elicited by the second (P2) and the first (P1)
stimuli. When applied, PPF was monitored for at least
5 min before, during and after the application of each drug.
The effects of ATP and ATPγS on PPF were evaluated by
measuring the P2/P1 ratio obtained before, during and 10
min after agonist application.
Chemicals
ATP (adenosine 5′-triphosphate), ATPγS [adenosine 5′-
O-(3-thiotriphosphate)], BBG (brilliant blue G) and BGO
136 (1-hydroxynaphthalene-3,6-disulfonic acid) were pur-
chased from Sigma (Milan, Italy). PPADS (pyridoxalphos-
phate-6-azophenyl-2′,4′-disulfonic acid tetrasodium salt),
ARL 67156 (6-N,N-diethyl-D-β,γ-dibromomethylene ATP),
suramin [8-(3-benzamido-4-methylbenzamido)naphthalene-
1,3,5-trisulfonic acid] and MRS 2179 (2′-deoxy-N
6-methyl-
adenosine 3′,5′-bisphosphate tetraammonium salt) were
obtained from Tocris (Bristol, UK). DPCPX (8-cyclo-
pentyl-1,3-dipropylxanthine) was purchased from Research
Biochemicals International (Natik, MA, USA). PV4 (hex-
apotassium dihydrogen monotitanoundecatungstocobaltate
(II) tridecahydrate, K6H2[TiW11CoO40]·13H2O) was syn-
thesized as described [69, 70].
Statistical analysis
Data were analyzed using Prism 3.02 software (Graphpad
Software, San Diego, CA, USA). All numerical data are
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not blocked by P2 purinergic antagonists. a Time course of fEPSP
amplitude before, during and after the application of different
concentrations of ATP. Each point in the graph represents the mean
± SE of fEPSP value measured as percent of baseline, pre-drug level.
Note that ATP was ineffective at 1 μM, whereas a significant
inhibition of fEPSP amplitude was observed starting from a concen-
tration of 10 μM( P<0.05, paired Student’s t-test). Upper panels
represent single traces recorded in a typical experiment before, during
and after 10 μM ATP application. Upper inset: stimulus-response
curves recorded before and after 30 μM ATP application illustrate the
potentiating effect of the P2 agonist on a wide range of stimulus
strengths in a typical experiment. fEPSP amplitude is expressed as
percent of the maximal value obtained under control conditions at the
highest stimulus strength. Note the increase in fEPSP amplitude
recorded 15 min after 30 μM ATP removal at stimulus intensities able
to evoke more than 50% of the maximal response. Lower inset: the
potentiating effect was prevented in the presence of 100 μM suramin.
b Columns in the graph summarize the average amplitude (mean ± SE)
of evoked fEPSP recorded from hippocampal slices under control
conditions, 5 min after superfusion of ATP alone and 5 min after ATP
superfusion in the presence of different purinergic antagonists. Note
that the inhibitory effect of ATP on fEPSP amplitude is not blocked by
the P2 antagonists PPADS and suramin, but only by the A1 adenosine
antagonist, DPCPX. *P<0.05, one-way ANOVA followed by New-
man-Keuls test versus pre-drug value. §P<0.05, one-way ANOVA
followed by Newman-Keuls test versus 10 μM ATP-treated slices.
Inset: bars in the graph represent the average of fEPSP amplitude 5
min before and during the last 5 min of PPADS superfusion (30 μM).
A significant difference was found between the two values (*P<0.05,
paired Student’s t-test)
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significance with the paired two-tailed Student’s t-test or by
analysis of variance (one-way ANOVA), as appropriate.
When significant differences were observed, the Newman-
Keuls multiple comparison test (one-way ANOVA) was
done. A value of P<0.05 was considered significant.
Results
Effects of ATP on CA1 hippocampal neurotransmission
In a first series of experiments, the effect of ATP on evoked
synaptic transmission in the CA1 region of rat hippocampal
slices was investigated. Figure 1a shows that a 10-min
application of ATP decreased the evoked fEPSP amplitude
in a concentration-dependent manner. A partial but statis-
tically significant inhibition was observed at a concentra-
tion of 10 μM ATP (20.3±2.5, P<0.0001, paired Student’s
t-test), while an almost complete inhibition was observed at
a concentration of 100 μM ATP (77.8±3.3%). As shown in
Fig. 1a, the effect was always reversible after a few minutes
of washout. The apparent EC50 value of ATP on fEPSP
inhibition was 59 μM [95% confidence limits (CL): 17–
198 μM]. These data are in line with previous results
demonstrating an ATP-mediated inhibition of extracellular-
ly recorded CA1 neurotransmission [32–35, 41]. At the
beginning of each experiment and 15 min after ATP
washout, a stimulus-response curve was delivered to verify
if there was a relatively “long-lasting” potentiation of
synaptic responses after ATP removal. Such an effect has
already been reported to occur in hippocampal slices [41,
71–76]. At concentrations of 1–10 μM we did not observe
any change in fEPSP amplitude after a 15-min application
of ATP at any stimulus intensity tested (data not shown).
On the contrary, an increase of 6.6±3.8% and of 12.3±
7.2% in fEPSP amplitude was observed at the highest
stimulus intensity tested after 30 μM (upper inset of
Fig. 1a) and 100 μM ATP superfusion, respectively.
The inhibitory effect of ATP on fEPSP amplitude was
not blocked by the P2 antagonists PPADS and suramin
(Fig. 1b). The two compounds were applied 10 min before,
during and 5 min after ATP superfusion. As shown in
Fig. 1b, 10 μM ATP in the presence of 30 μM PPADS still
elicited a fEPSP inhibition of 20±9%, which is not different
from that obtained with ATP alone. Similarly, 30 μMA T P
in the presence of 100 μM suramin evoked a 32±3.5%
fEPSP inhibition, which is not different from the 36±10.6%
fEPSP reduction obtained with 30 μM ATP alone. The
potentiation induced by 30 μM ATP was blocked in the
presence of 100 μM suramin (lower inset of Fig. 1a). It
should be noted that PPADS alone, but not suramin,
significantly reduced fEPSP amplitude of 5.21±1.6% (inset
of Fig. 1b; P<0.05, paired Student’s t-test, n=29) in
accordance with previous data obtained in the rat hippocam-
pus [43, 21] and prefrontal cortex [30, 36].
It is well known that extracellular ATP is rapidly
metabolized by membrane ecto-ATPases, leading to the
formation of ADP, AMP and adenosine. Adenosine A1
receptors are highly distributed in the CA1 hippocampus
and many effects of exogenous ATP have been attributed to
A1 adenosine receptor activation after ATP catabolism in
this brain region. For this reason, the effect of ATP was also
evaluated in the presence of the selective adenosine A1
antagonist DPCPX. The application of 100 nM DPCPX
30 min before ATP superfusion significantly increased
fEPSP amplitude (12.7±5.2% vs control, n=5, P<0.05,
paired Student’s t-test, data not shown). In addition, it
completely blocked the ATP-mediated reduction of fEPSP
(P<0.05, one-way ANOVA, Newman-Keuls post test,
Fig. 1b). We also investigated the effect of ATP in the
presence of different ecto-ATPase inhibitors: ARL 67156,
BGO 136 and PV4. As illustrated in Fig. 2, in the presence
of all these compounds the inhibitory effect on fEPSP
amplitude elicited by 10 μM ATP (35.8±6.4% in ATP
+ARL 67156, n=5; 38.2±3.6% in ATP+BGO 136, n=5;
35.2±6.1% in ATP+PV4, n=6) was significantly enhanced
Fig. 2 The inhibitory effect induced by ATP on fEPSP amplitude is
potentiated in the presence of different ecto-ATPases inhibitors.
Columns in the graph summarize the average amplitude (mean ±
SE) of evoked fEPSP recorded from hippocampal slices under control
conditions, 5 min after superfusion of ATP alone and 5 min after ATP
superfusion in the presence of different ecto-ATPases inhibitors. Note
that the inhibitory effect of ATP on fEPSP amplitude is potentiated by
BGO 136, PV4 and ARL 67156. *P<0.05 one-way ANOVA,
followed by Newman-Keuls test versus pre-drug value. §P<0.05,
one-way ANOVA followed by Newman-Keuls test versus 10 μM
ATP-treated slices
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blocked by DPCPX, a selective A1 adenosine receptor antagonist, and
by suramin, an aspecific P2 antagonist. a Time course of PS amplitude
before, during and after the application of different concentrations of
ATP. Each point in the graph represents the mean ± SE of the PS value
measured as percent of baseline, pre-drug level. Note that the P2
agonist was ineffective at 100 nM, whereas a significant inhibition of
fEPSP amplitude was observed starting from a concentration of 1 μM
(P<0.05, paired Student’s t-test). Upper panels represent single traces
recorded in a typical experiment before, during and after 10 μMA T P
application. The stimulus artefact was blanked and replaced by the
arrowhead. Upper inset: stimulus-response curves recorded before and
after 10 μM ATP application illustrate the potentiating effect of the P2
agonist on a wide range of stimulus strengths in a typical experiment.
PS amplitude is expressed as percent of the maximal value obtained
under control conditions at the highest stimulus strength. Note the
increase in PS amplitude recorded 15 min after 10 μM ATP removal at
stimulus intensities able to evoke more than 50% of the maximal
response. Lower inset: the potentiating effect was prevented in the
presence of 100 μM suramin. b Columns in the graph summarize the
average amplitude (mean ± SE) of evoked PS recorded from
hippocampal slices under control conditions, 5 min after superfusion
of ATP alone and 5 min after ATP superfusion in the presence of
different drugs. Note that the inhibitory effect of ATP on PS amplitude
is not modified by the P2 antagonist PPADS, while it is reduced by the
P2 antagonist suramin and is blocked by the A1 adenosine antagonist
DPCPX. *P<0.05, one-way ANOVA followed by Newman-Keuls test
versus pre-drug value. §P<0.05, one-way ANOVA followed by
Newman-Keuls test versus 10 μM ATP-treated slices. Inset: bars in
the graph represent the average of PS amplitude 5 min before and
during the last 5 min of 100 μM suramin application. A significant
difference was found between the two values (*P<0.05, paired
Student’s t-test)
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2.5%, P<0.05, one-way ANOVA, Newman-Keuls post
test).
The effects of ATP were also studied by recording
synaptic potentials at the somatic level of the CA1 region.
ATP (10 μM) induced a 66±7.1% decrease in PS amplitude
(P<0.0001, paired Student’s t-test, Fig. 3a) that was
reversed after few minutes’ washout. The apparent EC50
value of ATP on PS inhibition was 7 μM (95% CL: 1.5–
33 μM). When the stimulus-response curve was delivered
15 min after drug removal, a significant increase in PS
amplitude (P<0.05, paired Student’s t-test, n=7) was
observed at a stimulus intensity able to evoke a response
higher than 50% of the maximum (upper inset of Fig. 3a).
At the highest stimulus intensity tested, the increase was
14.8±3% (n=7).
No block of ATP-mediated inhibition of PS amplitude
was observed in the presence of PPADS (Fig. 3b). On the
contrary, 100 μM suramin significantly blocked the ATP-
mediated inhibition of the evoked potentials (P<0.05, one-
way ANOVA, Newman-Keuls post test, Fig. 3b) and
completely prevented the potentiation of the stimulus-
response curve (lower inset of Fig. 3a). In addition, it
induced a significant decrease in PS amplitude (12.8±3.4%,
P<0.05, paired Student’s t-test) when applied alone (inset
of Fig. 3b).
DPCPX (100 nM) applied 30 min before, during and 5
min after ATP superfusion antagonized the effects of
10 μM ATP on PS amplitude, as observed at the dendritic
level. DPCPX alone significantly increased PS amplitude
(60.3±11.4% vs control PS, n=6, P<0.05, paired Student’s
t-test, data not shown).
Effects of ATPγS on CA1 hippocampal neurotransmission
ATPγS, the metabolically stable ATP analogue, evoked a
concentration-dependent decrease in fEPSP amplitude
(Fig. 4a). A statistically significant reduction was evident
starting from a concentration of 3 μM( P<0.05, paired
Student’s t-test), and at 10 μM, ATPγS inhibited fEPSP
amplitude by 32.6±4.2% (Fig. 4a). The apparent EC50
value estimated for ATPγS on fEPSP inhibition was 22 μM
(95% CL: 4.6–106 μM). In all the slices in which we
recorded a stimulus-response curve before and 15 min after
ATPγS application, a statistically significant potentiation of
fEPSP (P<0.05, paired Student’s t-test, n=12) was ob-
served at intensities able to evoke a response higher than
50% of the maximum (upper inset of Fig. 4a).
The inhibitory effect of ATPγS on fEPSP amplitude was
significantly reduced both in the presence of 30 μM PPADS
and 10 μM MRS 2179. When higher concentrations of
PPADS (50 μM, Fig. 4b) and MRS 2179 (30 μM, data not
shown) were tested, no significant difference in the block of
ATPγS-induced inhibition was found. Both antagonists
completely prevented the potentiation of the stimulus-
response curve observed after 15 min of ATPγS washout
(lower inset of Fig. 4a) at the dendritic level. It should be
noted that the application of 10 μM MRS 2179 alone
caused a modest but significant reduction in fEPSP
amplitude (6.1±3.2%, P<0.05, paired Student’s t-test, inset
of Fig. 4b, n=15). Contrary to PPADS and MRS 2179, the
aspecific purinergic antagonist suramin (100 μM) did not
significantly inhibit ATPγS effects at the dendritic level
(Fig. 4b).
Surprisingly, the effect of ATPγS on fEPSP amplitude
was completely antagonized by the selective adenosine A1
antagonist, DPCPX (Fig. 4b). Evidence exists that even this
metabolically stable ATP analogue is partially converted to
adenosine [34]. To verify this possibility, we applied
ATPγS after a 30-min application of 50 μM ARL 67156.
However, under these experimental conditions, a 10-min
application of ATPγS induced an even more pronounced
effect on evoked neurotransmission (Fig. 4b). In fact, the
reduction in fEPSP amplitude elicited by 10 μMA T P γSi n
the presence of ARL 67156 was 68.2±4.6%, which is
significantly greater than that observed under control
conditions (P<0.001, one-way ANOVA, Newman-Keuls
post test).
At the somatic level, we delivered a cumulative
concentration-response curve (Fig. 5a) for ATPγS, since
no desensitization was observed during single drug appli-
cations (data not shown). Also in this case, the exogenous
application of ATPγS produced a concentration-dependent
decrease in PS amplitude. A significant effect was observed
starting from a concentration of 3 μM (17.4±8.6%, P<0.05,
paired Student’s t-test), while at a 30 μM concentration PS
was completely suppressed. The apparent EC50 value for
ATPγS on PS inhibition was 6 μM (95% CL: 1.2–28 μM).
Under these experimental conditions, a potentiation of PS
amplitude (37±12.1%) was observed after drug removal in
comparison to pre-drug values (see Fig. 5a, trace f) even
without eliciting a stimulus-response curve. The potentiation
of somatic response persisted for at least 30 min and was
also recorded during the stimulus-response curve (inset of
Fig. 5a) after 15 min of washout.
The application of 30 μM PPADS was unable to block
the ATPγS-mediated inhibition of PS amplitude (Fig. 5b)
and did not affect the potentiation of the stimulus-response
curve observed 15 min after drug removal (data not shown).
On the contrary, suramin (100 μM) significantly reduced
the ATPγS-mediated inhibition of PS amplitude (Fig. 5b)
and completely prevented the potentiation of the stimulus-
response curve (data not shown). As observed at the
dendritic level, the effect of ATPγS on PS amplitude was
completely antagonized by the adenosine A1 selective
antagonist, DPCPX (Fig. 5b).
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obtained for ATP and ATPγS at both the dendritic and
somatic levels. It can be noted that lower concentrations of
both P2 agonists are necessary to elicit the inhibitory effect
on PS amplitude in comparison to what is observed at the
dendritic level. In addition, the figure shows that ATPγSi s
more efficient in reducing fEPSP amplitude (but not PS
amplitude) in comparison to ATP.
Fig. 4 The inhibitory effect induced by ATPγS on fEPSP amplitude is
reduced by the P2 purinergic antagonists PPADS and MRS 2179 and
is enhanced by the ecto-ATPase inhibitor ARL 67156. a Time course
of fEPSP amplitude before, during and after the application of different
concentrations of ATPγS. Each point in the graph represents the mean
± SE of the fEPSP value measured as percent of baseline, pre-drug
level. Note that the P2 agonist was ineffective at 1 μM whereas a
significant inhibition of fEPSP amplitude was observed starting from a
concentration of 3 μM( P<0.05, paired Student’s t-test). Upper panels
represent single traces recorded in a typical experiment before, during
and after 10 μMA T P γS application. Upper inset: stimulus-response
curves recorded before and after 10 μMA T P γS application illustrate
the potentiating effect of the P2 agonist on a wide range of stimulus
strengths in a typical experiment. fEPSP amplitude is expressed as
percent of the maximal value obtained under control conditions at the
highest stimulus strength. Note the increase in fEPSP amplitude
recorded 15 min after 10 μMA T P γS removal at stimulus intensities
able to evoke more than 50% of the maximal response. Lower inset:
the potentiating effect was prevented in the presence of 10 μM MRS
2179. b Columns in the graph summarize the average amplitude (mean
± SE) of evoked fEPSP recorded from hippocampal slices under
control conditions, 5 min after superfusion of ATPγS alone and 5 min
after ATPγS superfusion in the presence of different drugs. Note that
the inhibitory effect of ATPγS on fEPSP amplitude is antagonized by
the P2 antagonists PPADS and MRS 2179, but not by suramin. The A1
adenosine antagonist DPCPX blocked the effect induced by 10 μM
ATPγS. In the presence of ARL 67156 the inhibitory effect of ATPγS
was increased. *P<0.05, one-way ANOVA followed by Newman-
Keuls test versus pre-drug value. §P<0.05, one-way ANOVA followed
by Newman-Keuls test versus 10 μMA T P γS-treated slices. Inset:
bars in the graph represent the average of fEPSP amplitude recorded
5 min before and during the last 5 min of 10 μM MRS 2179
application. A significant difference was found between the two values
(*P<0.05, paired Student’s t-test)
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subsequent potentiation of PS amplitude in the CA1 region of rat
hippocampus. a Time course of PS amplitude before, during and after
the application of different concentrations of ATPγS. Each point in the
graph represents the mean ± SE of the PS value measured as percent of
baseline, pre-drug level. Note that the P2 agonist was ineffective at 1 μM,
whereas a significant inhibition of fEPSP amplitude was observed starting
from a concentration of 3 μM( P<0.05, paired Student’s t-test). Note the
persistent increase in synaptic potential amplitude after drug removal. The
bar indicates the time duration of ATPγS application. Upper panels
represent single traces recorded in a typical experiment before, during and
after ATPγS application (10 μM). Inset: stimulus-response curve recorded
before and after 10 μMA T P γS application illustrate the potentiating
effect of the P2 agonist on a wide range of stimulus strengths in a typical
experiment. PS amplitude is expressed as percent of the maximal value
obtained under control conditions at the highest stimulus strength. Note
the increase in PS amplitude recorded 15 min after 10 μMA T P γS
removal at stimulus intensities able to evoke more than 20% of the
maximal response. b Columns in the graph summarize the average
amplitude (mean ± SE) of evoked PS recorded from hippocampal slices
under control conditions, 5 min after superfusion of ATPγS alone and 5
min after ATPγS superfusion in the presence of different purinergic
antagonists. Note that the inhibitory effect of ATPγSo nP Sa m p l i t u d ei s
not antagonized by the P2 antagonists PPADS, is reduced by the P2
antagonist suramin and is blocked by the A1 adenosine antagonist
DPCPX. *P<0.05, one-way ANOVA followed by Newman-Keuls test
versus respective pre-drug value. §P<0.05, one-way ANOVA followed
by Newman-Keuls test versus 10 μMA T P γS-treated slices
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of the rat hippocampus
In order to discern if the ATP- and ATPγS-mediated effects
on fEPSP amplitude were due to pre- or postsynaptic mecha-
nisms, we performed a PPF protocol (see “Methods”). As
shown in Table 1, a 10-min application of 10 μM ATP in-
creased PPF, an effect that is not statistically significant. On
the other hand, at a concentration of 100 μM, a significant
increase in PPF was observed (P<0.01, paired Student’s t-test).
Ten minutes application of ATPγS significantly increased PPF
starting from a concentration of 10 μM( T a b l e1).
To clarify if these effects on PPF were due to P1 or P2
receptor activation, we tested different purinergic antago-
nists. The action elicited by ATP was tested only in the
presence of DPCPX, since we previously demonstrated that
PPADS and suramin are not able to antagonize the ATP-
inhibitory effect on fEPSP amplitude.
DPCPX (100 nM) alone decreased PPF and fully
prevented the ATP-mediated effect. Since the effects of
ATPγS at the dendritic level were blocked by both P2 and
the A1 receptor antagonists, the effect was checked in the
presence of PPADS, MRS 2179 and DPCPX.
PPADS (30 μM) and MRS 2179 (10 μM), applied alone,
10 and 15 min before agonist superfusion, respectively,
significantly increased, per se, the P2/P1 ratio, but failed to
block the increase in PPF induced by 10 μMA T P γS.
DPCPX (100 nM) alone decreased PPF and fully prevented
the ATPγS-mediated effect (Table 1).
Effects of different purinergic antagonists on OGD-evoked
disruption of neurotransmission in the CA1 region of rat
hippocampal slices
The role of P2 purinergic receptor stimulation by endoge-
nous ATP released during in vitro OGD episodes on the
impairment of synaptic transmission was investigated using
P2-selective antagonists.
In a first series of experiments we characterized the
synaptic response of evoked fEPSPs following severe (7
min) OGD, an ischaemia-like insult that under our
experimental conditions has been constantly shown to
produce an irreversible loss of synaptic transmission [52,
53]. At the same time as the fEPSPs recordings, we also
monitored another important parameter of brain tissue
integrity, the DC shift produced by AD. It is well described
in the literature that AD is one of the major factors inducing
brain damage after an ischaemic episode [77].
Fig. 6 Concentration-response curves of ATP and ATPγS on dendritic
fEPSP and somatic PS responses. The graph shows the fitting curves of
concentration-dependent inhibitory effects of ATP and ATPγSo n
fEPSP and PS amplitude. Note that the curves obtained for both
purinergic agonists at the somatic level are shifted to the left in respect
tothoserecordedatthedendriticlevel.Inaddition,atthedendriticlevel,
the concentration-response curve obtained in the presence of ATPγSi s
steeper than that obtained in the presence of ATP
Table 1 Effects of P2 purinergic agonists and antagonists on paired-pulse facilitation in the CA1 hippocampal region
n P2/P1 ratio n P2/P1 ratio
Pre-drug 2 1.49±0.12 Pre-drug 5 1.31±0.01
10 μM ATP 2 1.59±0.13 100 nM DPCPX 5 1.29±0.05*
Wash 2 1.48±0.11 100 nM DPCPX + 100 μM ATP 5 1.29±0.04
Pre-drug 5 1.54±0.06 Pre-drug 4 1.32±0.02
100 μM ATP 5 2.16±0.06* 100 nM DPCPX 4 1.25±0.07*
Wash 5 1.56±0.06 100 nM DPCPX + 10 μMA T P γS 4 1.22±0.07
Pre-drug 9 1.48±0.08 Pre-drug 6 1.51±0.08
10 μMA T P γS 9 1.69±0.06* 30 μM PPADS 6 1.53±0.09*
Wash 8 1.47±0.09 30 μM PPADS + 10 μMA T P γS 6 1.90±0.12**
Pre-drug 4 1.49±0.03 Pre-drug 8 1.43±0.04
30 μMA T P γS 4 1.90±0.07* 10 μM MRS 8 1.46±0.04*
Wash 4 1.50±0.03 10 μM MRS + 10 μMA T P γS 8 1.67±0.08**
*P<0.05 from respective pre-drug value (paired Student’s t-test)
**P<0.05 from antagonist alone (paired Student’s t-test)
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fEPSP, which did not recover (4.2±1.9%, n=13) after
superfusion with oxygenated, glucose-containing aCSF as
monitored up to 80 min. In addition, in all control slices,
AD was recorded as a DC shift with a mean peak latency of
6.2±0.2 min after OGD initiation and a mean peak
amplitude of 6.1±0.6 mV (Table 2).
In the presence of PPADS, a non-selective P2 antagonist,
the irreversible block of synaptic transmission induced by
7-min OGD was prevented in five of the six slices tested.
As shown in Fig. 7a (open circles), 30 μM PPADS, applied
10 min before, during and 5 min after the OGD insult,
allowed a significant recovery of fEPSP amplitude within
15-min reperfusion with oxygenated and glucose-contain-
ing aCSF (from 4.2±2.1% of fEPSP recovery in control
slices to 79±16.6% in the presence of 30 μM PPADS, n=
6). Figure 7b shows that in this experimental group, only
three of six slices exposed to 7-min OGD presented a
sizeable AD (>1 mV) whose peak latency was delayed (7.1
±1 min) by PPADS 30 μM. One of these three slices, in
spite of the appearance of AD (2.5 mV, 30 s after oxygen
and glucose restoration) recovered a significant fraction
(78.5%) of original fEPSP amplitude after 20 min of
reperfusion.
As shown in Table 2, similar results were obtained in the
presence of different purinergic antagonists: suramin, MRS
2179 and BBG. In all cases the effect on recovery of fEPSP
amplitude (Fig. 7c) and AD inhibition was concentration-
dependent. In addition, in 8 of all 29 slices treated with the
P2 antagonists, no AD appearance was observed. In the
remaining 21 treated slices in which AD was recorded, its
appearance was significantly delayed (7.1±0.2 min after
OGD initiation). A significant recovery of fEPSP amplitude
(>15% of preischaemic value) was observed in 10 of the 21
treated slices in which AD emerged.
Discussion
Role of P2 receptors in hippocampal neurotransmission
under normoxic conditions
Our results demonstrate that ATP or its stable analogue
ATPγS modulate evoked synaptic transmission in the CA1
region of the rat hippocampus. The main effect, observed
within the first 2–3 min of drug application, is a reduction
in fEPSP and PS amplitude evoked by electrical stimulation
of the Schaffer collateral-commissural pathway. This effect
is concentration dependent and reversible after a few
minutes of washout. Another effect elicited by both ATP
and ATPγS is a significant potentiation of evoked
responses, recorded after drug removal and persisting for
at least 30 min.
The inhibitory effect observed during ATP application
has already been described and attributed to P1 [32–34]o r
to P2 receptor stimulation [35, 36].
Our observation that the selective A1 receptor antagonist
DPCPX blocks ATP-induced inhibition of synaptic responses
indicates that adenosine formed from ATP catabolism and
acting at A1 receptors is responsible for synaptic depression.
We would therefore expect that the ecto-ATPase inhibitors
tested (ARL 67156, BGO 136 and PV4) antagonize the ATP
inhibition of synaptic responses. On the contrary, all the ecto-
ATPase inhibitors potentiate the ATP inhibitory effect,
suggesting that they unmask a significant ATP-mediated
inhibitory action that is otherwise covered by adenosine
acting on A1 receptors. This interpretation is supported by the
observation that both ATP- and ATPγS-mediated inhibitory
responses are partially blocked by the unselective P2
antagonists suramin and PPADS and the selective P2Y1
antagonist MRS 2179. These observations indicate that, in
addition to P1 receptor activation, a P2 component is
Table 2 Effects of P2 purinergic receptor antagonists on CA1 hippocampal synaptic transmission after 7 min of OGD
a
AD appearance
(n/n)
AD peak time
(min)
AD peak
amplitude (mV)
fEPSP recovery ≥
15% (n/n)
fEPSP recovery (%)
after 15 min reperfusion
Control n=13 (13/13) 6.2±0.2 6.1±0.6 (0/13) 4.2±1.9
PPADS 10 μM( n=4) (3/4) 6.4±0.3 6.2±0.3 (3/4) 34.3±18.7
30 μM( n=6) (3/6) 7.1±0.9 5.9±0.4 (5/6) 65.9±20*
MRS 2179 1 μM( n=3) (2/3) 7.5±0.6 6.8±1.8 (2/3) 42.9±29.7
10 μM( n=5) (2/5) 7±0.3 4±1.8 (4/5) 79.2±18.2*
Suramin 10 μM( n=4) (3/4) 7.6±0.6 6±2.3 (2/4) 53.1±29.5
100 μM( n=3) (2/3) 6.6±0.5 4.7±1.1 (3/3) 80.5±11.9*
BBG 500 nM (n=4) (2/4) 6.1±0.3 7.9±0.4 (2/4) 57.6±31.6
1 μM( n=7) (4/7) 7.9±0.3 6.7±0.8 (4/7) 52.9±16.3*
aData are taken from slices receiving 7-min OGD under control conditions or in the presence of different P2 purinergic antagonists. Numbers in
parentheses (n/n) indicate the number of observations out of investigated slices. Time is calculated from OGD initiation. The amplitude of the final
fEPSP recovery is expressed as percent of baseline fEPSP value recorded 5 min before OGD application. *P<0.01 from control value (one-way
ANOVA followed by Newman-Keuls test)
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transmission in the CA1 area of the rat hippocampus.
The block of ATPγS effect by DPCPX is unexpected
because the agonist is considered a metabolically stable
ATP analogue. Our result is however in support of previous
observations that at least a fraction of ATPγS undergoes
enzymatic degradation and activates A1 adenosine receptors
[34]. An enzymatic degradation of ATPγSi sf u r t h e r
supported by the result that ARL 67156 potentiates the
inhibitory effect of this P2 agonist.
It has been suggested that, in hippocampal neurones,
ATP may activate DPCPX-sensitive P2 receptors [35]. The
existence of a heteromeric association between A1 and
P2Y1 receptors was demonstrated by co-localization stain-
ing, co-immunoprecipitation and bioluminescence reso-
nance energy transfer technology in HEK293T cells
transfected with both A1 and P2Y1 receptors [78, 79] and
in primary cultures of cortical, hippocampal and cerebellar
neurones [80]. Therefore, we could hypothesize that
DPCPX sensitivity of both ATP and ATPγS inhibitory
effects is attributable both to their enzymatic degradation to
adenosine and to the activation of the heteromeric A1-P2Y1
receptor. The fact that, in the present work, the P2Y1
antagonist MRS 2179 reduces the ATPγS-inhibitory effect
on fEPSP amplitude supports this notion.
Other groups have previously described a persistent
ATP-induced potentiation of CA1 hippocampal neurotrans-
mission [41, 71–76]. We clearly observed this phenomenon
after a prolonged application of ATPγS during somatic
recordings. When the dendritic potential was measured, the
increase in fEPSP amplitude elicited by both purinergic
agonists was detectable only by evoking a stimulus-
response curve 15 min after drug removal. The increase in
fEPSP amplitude was statistically significant only at the
highest stimulus intensities tested. The potentiating effect
elicited by ATP and ATPγS application is completely
blocked by P2 antagonists at both the dendritic and somatic
levels, demonstrating that it is due to P2 receptor
stimulation. It has to be noted that higher stimulus strengths
are needed to observe a potentiation of dendritic potentials
in comparison to somatic responses and that ATP and
ATPγS induce a significant potentiation of PS amplitude at
lower concentrations in respect to those required at the
dendritic level. Altogether, these data suggest that both
presynaptic P2 receptors modulating glutamate release and
postsynaptic P2 receptors modulating cell excitability are
involved in potentiation of CA1 hippocampal neurotrans-
mission. The P2 antagonists PPADS and MRS 2179 applied
alone significantly decrease fEPSP amplitude. At the soma-
tic level, only suramin diminishes the evoked responses.
These observations demonstrate that in the CA1 region of
rat hippocampal slices there is an endogenous tonic
activation of P2 receptors that contributes to excitatory
neurotransmission and is in agreement with those reported
in the rat hippocampus [21, 43] and prefrontal cortex [36,
30]. The varying efficacy of the P2 antagonists at the
dendritic and somatic levels suggests that different subtypes
of P2 receptors located in the pre- and postsynaptic
compartment are involved in the excitatory effect.
The role of P2 agonist application was also evaluated by
using a PPF protocol. The P2/P1 ratio was significantly
increased by ATP and ATPγS application. The same effect
has been described in hippocampal slices during exogenous
adenosine application by other groups [81] and is attributed
to an adenosine A1 receptor-mediated decrease of glutamate
release. Our data indicate that the increase in PPF elicited
by ATP application is completely blocked by DPCPX,
suggesting that it is effectively due to A1 receptor
stimulation after ATP conversion to adenosine. Similar
results are observed for ATPγS-induced PPF increase,
because it is not blocked by PPADS or MRS 2179, but
only by DPCPX. These data support the hypothesis that
part of ATPγS is converted to adenosine and activates A1
receptors. It should be noted that both purinergic antago-
nists (PPADS and MRS 2179) applied alone induced a
significant increase of PPF (P2\P1 ratio). This observation
indicates that ATP contributes to excitatory neurotransmis-
sion stimulating the release of glutamate. These results are
in line with those obtained by Rodrigues et al. [17]o n
hippocampal synaptosomes.
Role of P2 receptors in hippocampal neurotransmission
during OGD
The application of purinergic antagonists before, during and
after a severe (7 min) OGD insult allows a significant
recovery of fEPSP amplitude that is never observed in
control slices. The concentration range of the drug effects
falls within the Ki value estimated for all the antagonists in
the rat tissue [1, 65].
The mechanism by which these drugs protect hippocam-
palslices from theOGD-inducedirreversible lossof synaptic
transmission is likely correlated to AD appearance [53], a phe-
nomenon that contributes to cell damage during ischaemia (for
ar e v i e w :s e e[ 77]). In fact, in all 13 control slices, AD is
recorded within the 7-min OGD insult (mean latency of AD
appearance: 6.2±0.2 min after OGD initiation) and the
recovery of fEPSP amplitude after 15 min of reperfusion in
oxygenated and glucose-containing aCSF is always less than
10% of the preischaemic value. On the contrary, P2
antagonists both delay or block AD appearance and allow a
significant recovery of neurotransmission.
Our data suggest that hippocampal P2 receptors activat-
ed during OGD by endogenously released ATP exert a
deleterious role on CA1 neurotransmission by participating
in AD appearance.
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ischaemia was demonstratedinhippocampal slices byJuranyi
et al. [44] and Frenguelli et al. [82]w h or e p o r tap e a ki n
extracellular ATP concentration immediately before AD
appearance during an OGD insult. In agreement with our
results, the same authors show that this phenomenon is always
followed by the complete loss of synaptic transmission.
Under ischaemic conditions both direct and indirect
actions could account for P2 receptor antagonist-mediated
protection. A protective effect of P2 antagonists may be
attributed to a direct inhibition of Ca
2+ intracellular loading
in neuronal and glial cells [83, 84]. In fact, calcium is a
main toxicity factor under ischaemia [85]. Further possible
indirect protective effects of P2 receptor antagonists may
reside in the prevention of glutamate-evoked toxicity [86,
87] and in maintaining normal energetic stores [88].
Antagonism of P2 receptors during ischaemia might also
regulate intracellular pathways involved in ischaemia-
associated necrosis/apoptosis pathways such as expression
of the glucose-regulated protein GRP75 and of the caspase-
2 enzyme [89].
Among the antagonists checked in the present model, the
high selectivity of BBG indicates that P2X7 receptors are
clearly involved in the deleterious effects induced by OGD
in the CA1 hippocampal region. In addition, the participa-
tion of P2Y1 receptors in this effect is supported by the
efficacy of MRS 2179 in blocking AD appearance and
preventing the irreversible loss of neurotransmission in-
duced by a severe OGD.
These results are in agreement with the protective effect
exerted by P2 antagonists in in vitro OGD [50, 51] and in
vivo ischaemic conditions [47–49].
Fig. 7 Different purinergic antagonists are able to prevent the
irreversible loss of hippocampal CA1 neurotransmission after 7-min
OGD. a The graph shows the time courses of fEPSP amplitude before,
during 7 min of OGD and after reperfusion in normal oxygenated
aCSF in the absence and in the presence of 30 μM PPADS (open bar),
a P2 unselective receptor antagonist. Data (mean ± SE) are expressed
as a percent of the baseline values. b In the same groups of slices, AD
was recorded as a negative voltage shift in response to 7 min of OGD
in control slices (upper panel) and in the presence of 30 μM PPADS
(lower panel). Note that PPADS blocked AD appearance in three of
six slices and delayed the latency in the remaining three slices. Solid
bars indicate the time duration of OGD. c Columns in the graph
summarize the average recovery (mean ± SE) of fEPSP amplitude in
CA1 hippocampal slices after 7 min of OGD under control conditions
or in the presence of different P2 purinergic antagonists. Only slices
showing a fEPSP recovery >15% after 15 min of reperfusion were
included in the analysis. Note that all drugs allow a significant
recovery of fEPSP amplitude after 7 min of OGD. *P<0.001, one-way
ANOVA, followed by Newman-Keuls test versus control, untreated
slices
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We conclude that P2 receptors play an important role in CA1
hippocampal neurotransmission under both normoxic and
ischaemic conditions. Under normoxic conditions, both
inhibitory and excitatoryeffects are observed after application
of ATP or the stable analogue ATPγS. The inhibition of CA1
neurotransmission recorded during ATP application, under
our experimental conditions, is mostly due to the enzymatic
degradation to adenosine and subsequent activation of A1
receptors. The ATP analogue ATPγS evokes an inhibition of
hippocampal neurotransmission by both P2 and A1 adeno-
sine receptors. A later excitatory effect, as pointed out by
enhancement of fEPSP and PS amplitude, is attributable only
to P2 receptors. In addition, a tonic activation of P2 receptors
(likely located at a presynaptic level since their block
enhances PPF) contributes to the excitatory neurotransmis-
sion normally recorded in this brain area.
Under in vitro ischaemic conditions (OGD), a deleteri-
ous role of ATP is suggested by the observation that P2
antagonists allow the restoration of neurotransmission after
an otherwise lethal insult and block or delay the appearance
of AD.
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